AskBio announces first patient randomized in Phase 1 Trial of AB-1005

Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program

Phase 3 data expected in the second half of 2024

Biocon Biologics receives MHRA, UK Approval for Biosimilar Aflibercept ‘Yesafili’

Yesafili, received marketing authorization approval from the European Commission for the European Union

Glenmark Pharma reports Q2 FY24 loss at Rs. 62 Cr

European operations' revenue grew 58.4% to Rs 599.7 crore

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million

Zydus acquires UK based LiqMeds Group

Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution

USFDA inspection at Biocon Biologics' manufacturing facility in Johor, Malaysia

Lupin enters into BTA with Lupin Manufacturing Solutions

Lupin enters into BTA with Lupin Manufacturing Solutions

Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets

The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products